# NCT02159495 (NCT02159495)

> Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02159495
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: City of Hope Medical Center
- Conditions: Adult Acute Myeloid Leukemia in Remission; Acute Biphenotypic Leukemia; Early Relapse of Acute Myeloid Leukemia; Late Relapse of Acute Myeloid Leukemia; Recurrent Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Blastic Plasmacytoid Dendritic Cell Neoplasm; Acute Myeloid Leukemia; Adult Acute Lymphoblastic Leukemia; Interleukin-3 Receptor Subunit Alpha Positive; Minimal Residual Disease; Refractory Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia
- Interventions: cyclophosphamide; Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes; laboratory biomarker analysis; Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes; Fludarabine Phosphate
- Enrollment: 31
- Primary outcome: Dose-limiting toxicity (DLT) defined as any grade 3 or higher toxicity as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
- Primary outcome: Incidence of adverse events as assessed by NCI CTCAE version 4.0
- Primary outcome: Disease response (CR or CRi)

## Indexed commentary on NCT02159495 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct02159495